Use the hyperlinks, where available to access additional clinical trial information.
An ALLG Phase 2 study to Investigate Novel Triplets to Extend Remission with VENetoclax in Elderly (INTERVENE) Acute Myeloid Leukaemia
Australasian Leukaemia and Lymphoma Group (ALLG)
Other Non-Commercial Sponsor
Medical Research Future Fund
This trial includes a dose finding Run-in phase and a randomised phase. Eligible patients enrolled in the Run-in phase of the trial will received Low dose cytarabine (LDAC) and venetoclax, in combination with either midostaurin OR pracinostat to determine a recommended phase 2 dose. Eligible patients enrolled in the randomised phase of the trial will receive LDAC and venetoclax alone, or in combination with either midostaurin OR pracinostat at the recommended phase 2 dose.